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osting by EAbstract Objectives: Porous HA scaffolds are promising materials for tissue engineering because
they offer a tridimensional support and serve as template for cell proliferation and at last tissue for-
mation. Engipore provide a natural 3D scaffold with organic ﬁbrous material in bone. However,
how this material alters osteoblast activity to promote bone formation is poorly understood.
Materials and methods: To study how Engipore can induce osteoblast differentiation in mesenchy-
mal stem cells, the expression levels of bone related genes and mesenchymal stem cells marker were
analyzed.
Results: Engipore causes a signiﬁcant induction of osteoblast transcriptional factors like SP7 and
RUNX2 and of the bone-related gene osteocalcin (BGLAP).
The expression of CD105 was not signiﬁcantly changed in stem cells treated with Engipore with
respect to untreated cells, while SSP1 (osteopontin) was signiﬁcantly down expressed thus reducing
osteoclast activity.
Conclusions: The obtained results can be relevant to better understand the molecular mechanism of
bone regeneration.
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lsevier1. Introduction
Bone grafting procedures are undergoing a major shift from
autologous and allogeneic bone grafts to synthetic bone graft
substitutes (Valimaki and Aro, 2006). Biomaterials used in
bone regeneration are designed to be gradually resorbed by
the osteoclast and replaced by new bone formed through
osteoblastic activity (Ramaswamy et al., 2005). Large bone de-
fects still represent a major problem in orthopedics and maxil-
lofacial surgery. Traditional bone repair treatments can be
divided into two groups: the bone transport (Ilizarov technol-
ogy) and the graft transplant (autologous or allogeneic bone
162 V. Sollazzo et al.grafts). Thus far, none of these strategies have proven to be al-
ways resolving. As an alternative, a tissue engineering ap-
proach has been proposed where osteogenic cells, bioceramic
scaffolds, growth factors and physical forces concur to the
bone defect repair. Different sources of osteoprogenitor cells
have been suggested, bone marrow stromal cells (BMSC) being
in most cases the ﬁrst choice (Mastrogiacomo et al., 2005).
Biodegradable polymer/bioceramic composite scaffolds can
overcome the limitations of conventional ceramic bone substi-
tutes such as brittleness and difﬁculty in shaping (Kim et al.,
2006). Bioactive ceramics have been used clinically to repair
bone defects owing to their biological afﬁnity to living bone;
i.e. the capability of direct bonding to living bone, their so-
called bioactivity. However, currently available bioactive
ceramics do not satisfy every clinical application. Therefore,
the development of novel design of bioactive materials is nec-
essary. Bioactive ceramics show osteoconduction by formation
of biologically active bone-like apatite through chemical reac-
tion of the ceramic surface with surrounding body ﬂuid
(Ohtsuki et al., 2009). For optimal bone regeneration, scaffolds
need to ﬁt anatomically into the requisite bone defects and,
ideally, augment cell growth and differentiation (Kanczler
et al., 2009). Engipore is a new bioactive material with archi-
tecture very similar to the natural bone obtained using nano-
technologies. Engipore has a porosity rate of 90% offering
the ideal space for the new bone. Thanks to its porosity, Engi-
pore adsorb physiologic ﬂuids so that cytokines and growth
factors permeate in full thickness the material allowing bone
forming cells to colonize and differentiate inside. Engipore is
therefore useful in conducing bone regeneration in all the situ-
ations in which ﬁlling bone defects is needed.
Because few reports analyze the effects of Engipore on stem
cells (Mastrangelo et al., 2008) and none focus on the genetic ef-
fects, the expression of genes related to the osteoblast differentia-
tion was analyzed using cultures of bone marrow-derived human
mesenchymal stem cells (BM-hMSCs) treated with Engipore.
To investigate the osteogenic differentiation of BM-
hMSCs, the quantitative expression of the mRNA of speciﬁc
genes, like transcriptional factors (RUNX2 and SP7), bone-re-
lated genes (SPP1, COL1A1, COL3A1, BGLAP, ALPL, and
FOSL-1) and mesenchymal stem cells marker (ENG) was
examined by means of real-time reverse transcription-polymer-
ase chain reaction (real-time RT-PCR).2. Materials and methods
2.1. Stem preparation
Bone marrow-derived human mesenchymal stem cells (BM-
hMSCs) were obtained from healthy adult volunteers (mean
age 45 years) in accordance with the policy approved by the lo-
cal Ethical Committee (S. Orsola-Malpighi University Hospi-
tal, Bologna, Italy).
Bone marrow collected in heparinized tubes was diluted in
the ratio 1:3 with phosphate buffered saline (PBS) (Lonza,
Basel, Switzerland) and layered over a Ficoll-Histopaque gra-
dient (1.077 g/ml; Sigma, St. Louis, MO). The low-density
mononuclear cells were washed twice in PBS, counted and pla-
ted at 106/cm2 in cell culture ﬂasks (Falcon BD, Bedford, MA,
USA) in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM)
(Lonza, Basel, Switzerland) supplemented with 20% heat inac-tivated fetal bovine serum (FBS) (Lonza, Basel, Switzerland)
and antibiotics (100 U/ml penicillin, 100 lg/ml streptomycin)
(Sigma–Aldrich, Inc., St. Louis, MO, USA), and incubated
at 37 C in a humidiﬁed atmosphere with 5% CO2. After
1 week, the non-adherent cells were removed by replacing the
medium supplemented with 10% FBS. When the cultures were
near conﬂuence (after 2 weeks) the cells were recovered, by
treatment with 1· trypsin/EDTA solution (Sigma–Aldrich,
Inc., St. Louis, MO, USA), for cytometric analysis and func-
tional assays. BM-hMSCs were maintained and subcultured
for up to 10–15 passages.
2.2. Immunoﬂuorescence
Cells were washed with PBS for three times and ﬁxed with cold
methanol for 5 min at room temperature. After washing with
PBS, cells were blocked with bovine albumin 3% (Sigma–Al-
drich, Inc., St Louis, MO, USA) for 30 min at room tempera-
ture. The cells were incubated overnight sequentially at 4 C
with primary antibodies raised against CD105 1:200, mouse
(BD Biosciences, San Jose, CA, USA), CD73 1:200, mouse
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA),
CD90 1:200, mouse (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA), CD34 1:200, mouse (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA, USA). They were washed with PBS
and incubated for 1 h at room temperature with secondary
antibody conjugated-Rhodamine goat anti-mouse 1:200
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Sub-
sequently, the cells were mounted with the Vectashield
Mounting Medium with DAPI (Vector Laboratories, Inc.,
Burlingame, CA, USA) and observed under a ﬂuorescence
microscope (Eclipse TE 2000-E, Nikon Instruments S.p.a.,
Florence, Italy).
2.3. Cell culture
BM-hMSCs at fourth passage were grown in Alphamem med-
ium (Sigma–Aldrich, Inc., St. Louis, MO, USA) supplemented
with 10% fetal calf serum, antibiotics (penicillin 100 U/ml and
streptomycin 100 lg/ml – Sigma–Aldrich, Inc., St. Louis, MO,
USA) and aminoacids (L-Glutamine – Sigma–Aldrich, Inc., St.
Louis, MO, USA). The cells were incubated at 37 C in a
humidiﬁed atmosphere with 5% CO2.
For the assay, cells were collected and seeded at a density of
1 · 105 cells/ml into 9 cm2 (3 ml) wells by using 0.1% trypsin,
0.02% EDTA in Ca++ – and Mg – free Eagle’s buffer for cell
release.
One set of wells was added with Engipore (Finceramica,
Faenza, Italy) at the concentration of 2 mg/ml. Another set
of wells containing untreated cells was used as control. The
medium was changed every 3 days.
After 7 days, when cultures were sub-conﬂuent, the cells
were processed for RNA extraction.
2.4. RNA processing
Reverse transcription to cDNA was performed directly from
cultured cell lysate using the TaqMAn Gene Expression
Cells-to-Ct Kit (Ambion Inc., Austin, TX, USA), following
manufacturer’s instructions. Brieﬂy, cultured cells were lysed
with lysis buffer and RNA was released in this solution. The
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Engipore acts on human bone marrow stem cells 163cell lysates were reverse transcribed to cDNA using the RT En-
zyme Mix and appropriate RT buffer (Ambion Inc., Austin,
TX, USA).
Finally the cDNA was ampliﬁed by real-time PCR using
the included TaqMAn Gene Expression master mix and the
speciﬁc assay was designed for the investigated genes.
2.5. Real-time PCR
Expression was quantiﬁed using real-time RT-PCR. The gene
expression levels were normalized to the expression of the
housekeeping gene RPL13A and were expressed as fold
changes relative to the expression of the untreated BM-
hMSCs. Quantiﬁcation was done with the delta/delta calcula-
tion method (Livak and Schmittgen, 2001).
Forward and reverse primers and probes for the selected
genes were designed using primer express software (Applied
Biosystems, Foster City, CA, USA) and are listed in Table 1.
All PCR were performed in a 20 ll volume using the ABI
PRISM 7500 (Applied Biosystems, Foster City, CA, USA).
Each reaction contained 10 ll 2· TaqMAn universal PCR
master mix (Applied Biosystems, Foster City, CA, USA),
400 nM concentration of each primer and 200 nM of the
probe, and cDNA. The ampliﬁcation proﬁle was initiated by
10-min incubation at 95 C, followed by two-step ampliﬁcation
of 15 s at 95 C and 60 s at 60 C for 40 cycles. All experiments
were performed including non-template controls to exclude re-
agents contamination. PCRs were performed with two biolog-
ical replicates.
3. Results
BM-hMSCs were characterized by immunoﬂuorescence. The
cell surfaces were positive for mesenchymal stem cell markers,
CD105, CD90 and CD73 and negative for markers of hemato-
poietic origin, CD34 (Fig. 1).
Transcriptional expressions of several osteoblast-related
genes (RUNX2, SP7, SPP1, COLIA1, COL3A1, BGLAP,
ALPL and FOSL-1) and mesenchymal stem cells marker
(ENG) were examined after 7 days of supplement treatment
with Engipore (2 mg/ml).
Quantitative real-time RT-PCR of SP7, RUNX2 and
BGLAP showed a signiﬁcant induction after treatment with
Engipore. However, Engipore treatment did not affect the
mRNA expression of ENG and COL3A1 that were similar
in both treated and untreated BM-hMSCs. FOSL-1, COL1A1,
ALPL and SPP1 were decreased in the presence of Engipore at
day 7 (Fig. 2).T
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in4. Discussion
Research in regenerative medicine is developing at a signiﬁ-
cantly quick pace. Cell-based bone and cartilage replacement
is an evolving therapy aiming at the treatment of patients
who suffer from limb amputation, damaged tissues and
various bone and cartilage-related disorders and dental and
maxillofacial reconstructive surgery. Stem cells are undifferen-
tiated cells with the capability to regenerate into one or more
committed cell lineages. Stem cells isolated from multiple
sources have been ﬁnding widespread use to advance the ﬁeld
Figure 1 BM-hMSCs by indirect immunoﬂuorescence (Rhodamine). Cultured cells were positive for the mesenchymal stem cell markers
CD73 (a), CD90 (b), CD105 (c) and negative for the hematopoietic marker CD34 (d). Nucleuses were stained with DAPI. Original
magniﬁcation ·40.
Figure 2 Gene expression analysis of BM-hMSCs after 7 days of
treatment with Engipore.
164 V. Sollazzo et al.of tissue repair (El Tamer and Reis, 2009). Bone regeneration
for the defects in revision surgery of joint replacement is an
increasingly important issue. To repair bone defects, bone cell
activation by growth factors using synthetic resorbable scaf-
fold is a useful and safe option (Hayashi et al., 2009). Syntheticand biological materials are increasingly used to provide tem-
porary or permanent scaffolds for bone regeneration (Malm-
strom et al., 2009). Bone regeneration by autologous cell
transplantation in combination with a biodegradable scaffold
is one of the most promising techniques being developed in
craniofacial and orthopedic surgeries (Mastrangelo et al.,
2008). Tissue engineering approaches attempt to create tissue
replacement by culturing autologous cells onto three-dimen-
sional matrixes that facilitate cell progenitor migration, prolif-
eration and differentiation (Zhang et al., 2006). Porous HA
scaffolds are promising materials for tissue engineering be-
cause they offer a tridimensional support and serve as template
for cell proliferation and at last tissue formation (Haynesworth
et al., 1992; Ferlazzo et al., 2006). Engipore provide a natural
3D scaffold with organic ﬁbrous material in bone (Yoshikawa
et al., 1996).
In order to get more inside how Engipore acts on BM-
hMSCs, changes in the expression of bone-related marker
genes (RUNX2, SP7, SPP1, COLIA1, COL3A1, BGLAP,
ALPL and FOSL-1) and mesenchymal stem cells marker
(CD105) were investigated by real-time RT-PCR.
Mesenchymal stem cells are deﬁned as self-renewable, mul-
tipotent progenitor cells with the ability to differentiate, under
adequate stimuli, into several mesenchymal lineages, including
osteoblasts (Alhadlaq and Mao, 2004).
Engipore acts on human bone marrow stem cells 165In our study, mesenchymal stem cells from human bone
marrow were isolated and characterized by morphology and
immunophenotype. Isolated BM-hMSCs showed ﬁbroblast-
like morphology and were positive for MSC surface molecules
(CD90, CD105, and CD73) and negative for markers of hae-
matopoietic progenitors (CD34).
After 7 day of treatment with Engipore, the expression lev-
els of osteodifferentiation genes were measured by relative
quantiﬁcation methods using real-time RT-PCR.
Two osteoblast-speciﬁc genes, RUNX2 and BGLAP, that
are generally express by osteoblast in the early stage of their
differentiation (Lian et al., 2003) were up-regulated in treated
BM-hMSCs. RUNX2 is the most speciﬁc osteoblast transcrip-
tion factor and is a prerequisite for osteoblast differentiation
and consequently mineralization.
Another up-regulated gene was SP7, a zinc ﬁnger transcrip-
tion factor that regulates bone formation and osteoblast differ-
entiation in vitro and in vivo and that is expressed in the early
stage of osteogenic differentiation.
ENG (CD105), a surface marker used to deﬁne a bone mar-
row stromal cell population capable of multilineage differenti-
ation (Jin et al., 2009), was not affected in treated BM-hMSCs
with respect to control at 7 days.
COL3A1 encodes the pro-alpha1 chains of type III colla-
gen, a ﬁbrillar collagen that was found in extensible connective
tissues (Chan et al., 2008).
Expression of ENG and COL3A1 did not have signiﬁcant
change in treated cells with respect to control after 7 day of
treatment therefore meaning that Engipore do not affect nor-
mal process of differentiation and matrix synthesis in the early
stages of BM-hMSCs differentiation.
Alkaline phosphatase regulates mineralization of bone ma-
trix and was down regulated. Several studies demonstrated
that the potency of individual substances to induce alkaline
phosphatase varies in a species-dependent manner. Glucocor-
ticoids such as dexamethasone are potent inducers in human
and rat stromal cells, but they have no effect on alkaline phos-
phatase activity in mouse stromal cells (Leboy et al., 1991;
Beresford et al., 1994). At the contrary, bone morphogenetic
proteins (BMPs) are potent inducers of osteogenesis in both
mouse and rat bone marrow stromal cells (Balk et al., 1997)
but Diefenderfer et al. showed that BMP-2 alone is a poor
osteoblast inducer in human marrow-derived stromal cells
(Diefenderfer et al., 2003).
Another investigated gene was FOSL-1 that encodes for
Fra-1, a component of the dimeric transcription factor activa-
tor protein-1 (Ap-1), which is composed mainly of Fos (c-Fos,
FosB, Fra-1 and Fra-2) and Jun proteins (c-Jun, JunB and
JunD).
Ap-1 sites are present in the promoters of many develop-
mentally regulated osteoblast genes, including alkaline phos-
phatase, collagen I, and osteocalcin.
McCabe et al. (1996) demonstrated that differential expres-
sion of Fos and Jun family members could play a role in the
developmental regulation of bone-speciﬁc gene expression
and, as a result, may be functionally signiﬁcant for osteoblast
differentiation.
In our study, FOSL-1 was down regulated, probably be-
cause cells were at early stage of differentiation. Kim et al.
(2008) studying the effect of new anabolic agents that stimulate
bone formation ﬁnd that this gene is activated in the late stage
of differentiation, during the calcium deposition.Engipore also modulate the expression of genes encoding
for collagenic extracellular matrix proteins like collagen type
1a1 (COL1A1). Collagen type 1 is the most abundant in the
human organism (Suuriniemi et al., 2006). In our study,
COL1A1 was signiﬁcantly down expressed as compared to
the control when exposed to Engipore probably because this
gene is activated in the late stage of differentiation and are re-
lated to extracellular matrix synthesis.
SSP1 encodes osteopontin, which is a phosphoglycoprotein
of bone matrix and it is the most representative noncollagenic
component of extracellular bone matrix (McKee et al., 1993).
Osteopontin is actively involved in bone resorbitive processes
directly by osteoclasts (Dodds et al., 1995). Osteopontin pro-
duced by osteoblasts shows high afﬁnity to the molecules of
hydroxylapatite in extracellular matrix and it is chemo-attrac-
tant to osteoclasts (Ohtsuki et al., 2009). In our study, osteo-
pontin was signiﬁcantly down expressed when exposed to
Engipore. Therefore Engipore seems to act by reducing bone
resorption processes.
The present study shows the effect of Engipore on BM-
hMSCs in the early differentiation stages: Engipore is an indu-
cer of osteogenesis on human stem cells, as RUNX2 is imme-
diately activated, while reducing osteoclastic activity, as SSP1
is down expressed. Moreover, we have chosen to perform the
experiment after 7 days in order to get information on the
early stages of stimulation. It is our understanding, therefore,
that more investigations with different time points are needed
in order to get a global comprehension of the molecular events
related to Engipore action. The reported model is useful to
investigate the effect of different substances on stem cells.References
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